INVITRIS

We are the manufacturing layer to turn AI into medicine. Invitris (YC W23, Munich) builds autonomous cell-free biomanufacturing to scale personalized production of AI-designed drugs, starting with phage therapeutics against antibiotic-resistant infections. Opening a $1-2M Final Seed in September to boost automation ahead of the $25M Series A (50% secured). Preview: https://literate-gym-e35.notion.site/INVITRIS-Final-Seed-September-2026-3b916efacd0381e5ba74d2bee52ec2af